Centre Oscar Lambret — Clinical Trial Site

183 Registered trials

85 Currently recruiting

Organisation

Centre Oscar Lambret

Location

Lille, France

Identifier

ORG-100008539

Address

3 Rue Frederic Combemale, 59000, France

Departments

105: Cancérologie Générale
2314: Centre Oscar Lambret
59
Canc. Chir. Gyn., Pavillon Paul Gellé
Cancérologie Sénologique
Cervico-facial and thoracis onclogy and gynaecology
Cervico-facial and thoracis oncology
Departament oncologie
Departement d'Oncologie Medicale
Département de cancérologie Cervico-Faciale
Département de Cancérologie Gynécologie
Département de Cancérologie Gynécologique
Département de Cancérologie Sénologique
Département de radiothérapie
Department of onco-Gynaecology
Dept. of Oncology
Direction de la Recherche Clinique et de l'innovation
Direction de la Recherche Clinique et de l'Innovation (DRCI) - medical oncology
DRCI Investigation
Gastroenterology and digestive cancer department
General Oncology
Gynecological surgery
Gynécologie
Head and neck surgery
Hôpital Oscar Lambret
Medical oncology
Medical Oncology Department
Medical oncology department in Pediatrics
N/A
NA
Nord
Onco-pédiatrie
Oncologie
Oncologie générale
Oncologie Medicale
ONCOLOGIE OPTION MEDICALE
Oncologie Radiothérapie
Oncologue
oncology
Oncology department
Oncology for pediatrics
Oncology service
ORL and Facial Surgery
ORL et Chirurgie cervico-faciale
Paediatric Oncology
Ped Oncology
Pediatric oncology
Pediatric oncology department
Pediatric unit - Oncology
Pediatric unit, oncology department
Pediatric Unit. Oncology department
Pediatrics
pediatrie
Pôle d'Oncologie Médicale
Pôle oncologie
Pole Oncologie médicale
Pôle oncologie, comité pédiatrique
Pôle oncologie, comité sénologique
Radiation Oncology
Radiothérapie
Radiotherapist
Radiotherapy
Radiotherapy for adults
Radiotherapy for pediatrics
Senology
Service d'Oncologie médicale
Service d’Oncologie Générale
Service de radiothérapie
Unité d’Onco-Pédiatrie
Unité d’Oncologie pédiatrique, Centre Oscar Lambret de Lille Centre régional de lutte contre le canc
Urological and Digestive Oncology

Clinical trials at this site (183)

Search interface

Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Metastatic Gastric Adenocarcinoma 5 2021-08-19
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Solid tumors 4 2021-03-15
GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac… Ended

2024-510714-32-00 Patiens with locally advanced/metastatic endometrial ca 4 2020-12-10
RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Ended

2022-502642-27-00 RElapse in previously irradiated Prostate bed 9 2020-11-26
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Localised unresectable adenocarcinoma or squamous cell 4 2019-05-13
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy Ended

2024-510713-15-00 Localised and operable soft tissue sarcomas 4 2018-07-30
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-506390-35-00 Patients with Advanced Solid Tumors 1 2017-04-19
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended

2024-513972-16-00 - Resected tumors of sinuses or salivary glands - Non-o 5 2017-01-30
RISK OF INFERTILITY RELATED TO ADJUVANT CHEMOTHERAPY IN YOUNG BREAST CANCER PATIENTS: OOCYTE/EMBRYO CRYOPRESERVATION Ended

2024-513078-23-00 breast cancer in young women 4 2016-12-02
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended

2022-501253-37-00 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarc 4 2016-02-02
RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT INITIAL STAGING PROTOCOLS IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE A… Ended

2024-513079-42-00 Intermediate-risk, high risk endometrial cancer 5 2015-11-19
Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap… Ended

2024-513976-16-00 squamous cell carcinomas of the larynx or hypopharynx l 5 2015-06-26
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended

2024-513455-33-00 Bone sarcoma 4 2014-09-11